Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright dropped their target price on Trevena from $9.00 to $5.00 and set a buy rating on the stock in a report on Thursday, May 16th.

Trevena Stock Up 5.3 %

NASDAQ:TRVN opened at $0.24 on Friday. The stock has a market capitalization of $4.37 million, a price-to-earnings ratio of -0.09 and a beta of 1.06. Trevena has a 52 week low of $0.19 and a 52 week high of $1.12. The stock’s fifty day moving average is $0.31 and its two-hundred day moving average is $0.44.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.01. The company had revenue of $0.02 million during the quarter. On average, sell-side analysts expect that Trevena will post -1.29 EPS for the current fiscal year.

Hedge Funds Weigh In On Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC purchased a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent quarter. 13.56% of the stock is currently owned by institutional investors and hedge funds.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.